LAL-D: A LIFE-THREATENING GENETIC DISEASE WITH ONGOING, PROGRESSIVE, MULTIORGAN DAMAGE LEADING TO PREMATURE DEATH1
In patients with Lysosomal Acid Lipase Deficiency (LAL-D),
uncontrolled accumulation of cholesteryl esters (CEs) and triglycerides (TGs) leads to systemic complications1
LEARN TO DIAGNOSE LAL-D
Reference: 1. Bernstein DL, et al. J Hepatol. 2013;58:1230-43. doi:10.1016/j.jhep.2013.02.014.
You are leaving www.laldsource.com.
You are leaving www.laldsource.com, a website of Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc. does not review or control the content of non-Alexion websites, and this hyperlink does not constitute an endorsement by Alexion of the site’s content. Alexion’s privacy procedures do not apply to the owners of a non-Alexion website.
Welcome to LALDSOURCE.COM
I am a healthcare professional and I would like more information on Lysosomal Acid Lipase Deficiency (LAL-D)